Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease
GLP-1 RAs are safe and effective for weight loss in patients with ACHD with beneficial effects on glycemic control.
Authors
- Francisco López-Jiménez (ORCID: https://orcid.org/0000-0001-5788-9734)
- Kyla Lara-Breitinger (ORCID: https://orcid.org/0000-0001-9724-3065)
- Andro Košec (ORCID: https://orcid.org/0000-0001-7864-2060)
- C. Charles Jain (ORCID: https://orcid.org/0000-0002-1116-8541)
- William R. Miranda (ORCID: https://orcid.org/0000-0001-8864-8474)
- Maan Jokhadar (ORCID: https://orcid.org/0009-0009-0882-2133)
- Alexander C. Egbe (ORCID: https://orcid.org/0000-0002-8810-3631)
- Luke James Burchill (ORCID: https://orcid.org/0000-0001-9786-1840)
- Heidi M. Connolly (ORCID: https://orcid.org/0000-0003-0666-0344)
- Nishat Shama (ORCID: https://orcid.org/0000-0001-9859-7949)
- Rashmi Thapa
- S Alm
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1016/j.jacadv.2025.101674
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88